|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Chemonaive | Prior Taxane | Two prior chemo | Total |
|  | N=41 | N=51 | N=24 | N=116 |
| (N=116) | N | % | N | % | N | % | N | % |
| Age (years) Median | 70 |  | 67 |  | 73 |  | 70 |  |
| Range | 45-86 |  | 45-88 |  | 57-85 |  | 45-88 |  |
|  |  |  |  |  |  |  |  |  |
| Race |  |  |  |  |  |  |  |  |
| Caucasian | 39 | 95% | 46 | 90% | 23 | 100% | 108 | 94% |
| Black | 2 | 5% | 3 | 6% |  |  | 5 | 4% |
| Asian |  |  | 1 | 2% |  |  | 1 | 1% |
| Native American |  |  | 1 | 2% |  |  | 1 | 1% |
| Other/Unknown |  |  |  |  | 1 |  | 1 |  |
|  |  |  |  |  |  |  |  |  |
| ECOG PS |  |  |  |  |  |  |  |  |
| 0 | 27 | 66% | 18 | 35% | 11 | 46% | 56 | 48% |
| 1 | 11 | 27% | 28 | 55% | 10 | 42% | 49 | 42% |
| 2 | 3 | 7% | 5 | 10% | 3 | 13% | 11 | 9% |
|  |  |  |  |  |  |  |  |  |
| PSA prior to treatment |  |  |  |  |  |  |  |  |
| Median | 35.6 |  | 78.9 |  | 169 |  | 62.7 |  |
| Range | 2.2-769.0 |  | 1.2-4835.7 |  | 15.9-4103.9 |  | 1.2-4835.7 |  |
|  |  |  |  |  |  |  |  |  |
| Prior Treatment |  |  |  |  |  |  |  |  |
| Hormonal therapy | 39 | 95% | 51 | 100% | 24 | 100% | 114 | 98% |
| Radiation therapy | 25 | 61% | 35 | 69% | 17 | 71% | 77 | 66% |
| Surgery | 20 | 49% | 15 | 29% | 10 | 42% | 45 | 39% |
| Other | 5 | 12% | 7 | 14% | 5 | 21% | 17 | 15% |
|  |  |  |  |  |  |  |  |  |
| Gleason score  |  |  |  |  |  |  |  |  |
| <7 | 10 | 28% | 8 | 16% | 3 | 15% | 21 | 20% |
|  7 | 11 | 31% | 19 | 38% | 7 | 35% | 37 | 35% |
| >7 | 15 | 42% | 23 | 46% | 10 | 50% | 48 | 45% |
| Unknown | 5 |  | 1 |  | 4 |  | 10 |  |
|  |  |  |  |  |  |  |  |  |
| Location of metastasis |  |  |  |  |  |  |  |  |
| Lung | 6 | 15% | 13 | 25% | 3 | 13% | 22 | 19% |
| Pleura | 1 | 2% | 1 | 2% | 2 | 8% | 4 | 3% |
| Liver | 3 | 7% | 10 | 20% | 3 | 13% | 16 | 14% |
| Bone marrow |  |  | 2 | 4% |  |  | 2 | 2% |
| Bone | 29 | 71% | 45 | 88% | 21 | 88% | 95 | 82% |
| Lymph nodes | 15 | 37% | 23 | 45% | 7 | 29% | 45 | 39% |
|  |  |  |  |  |  |  |  |  |
| Number of metastatic sites |  |  |  |  |  |  |  |  |
| Median | 1 |  | 2 |  | 1 |  | 1.5 |  |
| Range | 0-3 |  | 0-4 |  | 0-4 |  | 0-4 |  |
|  |  |  |  |  |  |  |  |  |
| Symptoms at baseline |  |  |  |  |  |  |  |  |
| Bone pain | 13 | 32% | 24 | 47% | 10 | 42% | 47 | 41% |
| Genitourinary | 13 | 32% | 12 | 24% | 7 | 29% | 32 | 28% |
| Gastrointestinal | 4 | 10% | 9 | 18% | 5 | 21% | 18 | 16% |
| Nausea/vomiting | 1 | 2% | 4 | 8% | 3 | 13% | 8 | 7% |
| Nervous system  |  |  | 4 | 8% | 2 | 8% | 6 | 5% |
|  |  |  |  |  |  |  |  |  |
| Disease status at registration |  |  |  |  |  |  |  |  |
| Stable mets; rising PSA | 9 | 22% | 8 | 16% | 5 | 21% | 22 | 19% |
| Progressive mets | 32 | 78% | 43 | 84% | 19 | 79% | 94 | 81% |
|  |  |  |  |  |  |  |  |  |

Supplementary data table 1. Patient characteristics